Evaluating lncRNA Identification and Risk Management Perspectives for Strategic Decision-Making

Resumen

The pharmaceutical industry increasingly relies on long non-coding RNA (lncRNA) identification for drug development, precision medicine, and therapeutic advancements. However, the strategic decision-making process regarding lncRNA adoption requires a structured evaluation of its key determinants. Furthermore, the significance of the risk management practices being followed by such an industry can be viewed from their managerial implications and subsequent decision making. This study examines the impact of lncRNA identification and risk management on strategic decision-making in pharmaceutical organizations using Structural Equation Modeling in SmartPLS. The measurement model's reliability and validity were confirmed, ensuring the robustness of the results and the adopted items for the estimation purpose. The findings confirmed that both lncRNA identification and risk management have a positive and significant impact on strategic decision-making, reinforcing their critical role in shaping business strategies. These insights provide pharmaceutical executives and decision-makers with a data-driven foundation for evaluating and integrating lncRNA identification into strategic frameworks while managing associated risks effectively.